Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biogen Idec Inc Raises FY 2013 Revenue Guidance; Reaffirms FY 2013 EPS Guidance-Conference Call


Monday, 10 Jun 2013 01:30pm EDT 

Biogen Idec Inc announced that for fiscal 2013, it expects to see high teens revenue growth and then non-GAAP diluted earnings per share between $7.80 and $7.90. The Company reported revenues of $5.5 billion in fiscal 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $6.55 billion for fiscal 2013. 

Company Quote

323.5
-7.31 -2.21%
1 Oct 2014